Patents Examined by Sean McGarry
  • Patent number: 10988763
    Abstract: The invention relates to antisense oligonucleotides that are capable of bringing about specific editing of a target nucleotide (adenosine) in a target RNA in a eukaryotic cell, wherein said oligonucleotide does not, in itself, form an intramolecular hairpin or stem-loop structure, and wherein said oligonucleotide comprises a cytidine (a non-complementary nucleotide) or a uridine in position opposite to the target adenosine to be edited in the target RNA region.
    Type: Grant
    Filed: June 22, 2017
    Date of Patent: April 27, 2021
    Inventors: Janne Juha Turunen, Petra Geziena De Bruijn, Bart Klein, Roxana Simona Redis, Lenka Van Sint Fiet
  • Patent number: 10988765
    Abstract: Disclosed herein are compositions and methods for attenuating detoxification response and related symptoms thereof induced by translation defect. The compositions and methods herein are useful for attenuating detoxification response and/or treat related symptoms thereof in subjects comprising translation defect. The composition and methods herein are also useful for improving pharmacokinetics of a pharmaceutical compound.
    Type: Grant
    Filed: August 29, 2016
    Date of Patent: April 27, 2021
    Inventors: Gary Ruvkun, J. Amaranath Govindan
  • Patent number: 10982209
    Abstract: Provided are a method for constructing a suppressor tRNA, and 19 suppressor tRNAs corresponding to three termination codons, a plasmid, a vector or a kit comprising the above-mentioned tRNA. Also provided are use of the above-mentioned tRNA, plasmid, vector or kit in the manufacture of a medicament for treating a hereditary disease or a cancer caused by a nonsense mutation of a gene. Also provided are a method for evaluating the efficiency of a suppressor tRNA for reading through a nonsense mutation, and a method for restoring the expression of a truncated protein of a nonsense mutant of a pathogenic gene in a monogenic hereditary disease and a tumor suppressor gene in a tumor cell.
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: April 20, 2021
    Inventors: Qing Xia, Tianchang Wang, Qi Yang
  • Patent number: 10975374
    Abstract: A composition for treating cancer is disclosed. The composition includes a lentiviral particle and an aminobisphosphonate drug. The lentiviral particle is capable of infecting a target cell, such as a cancer cell, and includes an envelope protein optimized for targeting such target cell and a viral vector. The viral vector includes a small RNA optimized to target an FDPS mRNA sequence. The aminobisphosphonate drug includes zoledronic acid.
    Type: Grant
    Filed: July 30, 2020
    Date of Patent: April 13, 2021
    Assignee: American Gene Technologies International Inc.
    Inventors: Tyler Lahusen, Mei-Ling Liou, Lingzhi Xiao, Haishan Li, Charles David Pauza
  • Patent number: 10975373
    Abstract: A method of treating a bipolar disorder in a subject in need thereof is disclosed. The method comprising administering to the subject sa therapeutically effective amount of a miR-135, a precursor thereof or a nucleic acid molecule encoding said miR-135 or said precursor thereof, thereby treating the bipolar disorder. Methods of diagnosing a mood disorder in a human subject and of monitoring treatment of an anti-depressant drug or a medicament for the treatment of a mood disorder are also disclosed.
    Type: Grant
    Filed: November 5, 2018
    Date of Patent: April 13, 2021
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Alon Chen, Orna Issler
  • Patent number: 10961589
    Abstract: A method for treating HER2 positive breast cancer in a subject in need thereof includes administering to cancer cells of the subject an agent effective to modulate the level of HER2-associated RNA in the breast cancer cells of the subject.
    Type: Grant
    Filed: March 7, 2016
    Date of Patent: March 30, 2021
    Inventors: Ahmad Khalil, Lyndsay Harris
  • Patent number: 10954299
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of pulmonary bacterial infections. The increasing burden of antimicrobial resistance coupled with the decreasing number of antibiotics in development has urged for strategies to elaborate new therapies. The inventors showed a therapeutic effect of IL-20 receptor 10 antagonists in pulmonary bacterial infection mouse model. Indeed, they demonstrated that treatment with IL-20 receptor antagonists reduces bacterial burden, cellular infiltration and inflammation in bronchoalveolar lavage fluid (BALF) and lung. In particular, the present invention relates to an antagonist of IL-20 cytokines, or/and an antagonist of IL-20RB receptor for use in a method for the treatment of pulmonary bacterial infections in a subject in 15 need thereof.
    Type: Grant
    Filed: May 24, 2017
    Date of Patent: March 23, 2021
    Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale), Centre National de la Recherche Scientifique (CNRS), Institut Paseur de Lille, Universitéde Lille
    Inventors: Philippe Gosset, Fahima Madouri, Muriel Pichavant
  • Patent number: 10946107
    Abstract: The invention relates to polynucleotide agents targeting an hydroxyacid oxidase (HAO1) gene, and methods of using such polynucleotide agents to inhibit expression of HAO1 and to treat subjects having an HAO1-associated disease, e.g., hyperoxaluria.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: March 16, 2021
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventor: Gregory Hinkle
  • Patent number: 10941405
    Abstract: Disclosed herein include compositions and methods of modulating protein expression that utilizes an activator or a repressor of a non-sense mediated RNA decay switch exon (NSE). In some embodiments, also included herein are compositions and methods of modulating protein expression that uses an agent that targets a transposed element.
    Type: Grant
    Filed: December 7, 2018
    Date of Patent: March 9, 2021
    Assignee: University of Southampton
    Inventors: Igor Vorechovsky, Jana Kralovicova
  • Patent number: 10941451
    Abstract: The present invention relates to panels of methylation and mi RNA marker as well as their use in the prognosing, diagnosing and/or treatment of cancer, means for detecting said marker, kits comprising said means, and devices for analysing the marker panel.
    Type: Grant
    Filed: February 24, 2016
    Date of Patent: March 9, 2021
    Inventors: Barbara Burwinkel, Rongxi Yang, Andreas Schneeweiss
  • Patent number: 10933081
    Abstract: The present invention provides methods comprising the in vivo delivery of small nucleic acid molecules capable of mediating RNA interference and reducing the expression of myostatin, wherein the small nucleic acid molecules are introduced to a subject by systemic administration. Specifically, the invention relates to methods comprising the in vivo delivery of short interfering nucleic acid (siRNA) molecules that target a myostatin gene expressed by a subject, wherein the siRNA molecule is conjugated to a lipophilic moiety, such as cholesterol. The myostatin siRNA conjugates that are delivered as per the methods disclosed are useful to modulate the in vivo expression of myostatin, increase muscle mass or enhance muscle performance. Use of the disclosed methods is further indicated for treating musculoskeletal diseases or disorders or diseases or disorders that result in conditions in which muscle is adversely affected.
    Type: Grant
    Filed: September 20, 2017
    Date of Patent: March 2, 2021
    Inventors: Vasant R. Jadhav, Rubina Parmar, Laura Sepp-Lorenzino, Muthiah Manoharan
  • Patent number: 10934545
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the ANGPTL3 gene, as well as methods of inhibiting expression of ANGPTL3 and methods of treating subjects having a disorder of lipid metabolism, such as hyperlipidemia or hypertriglyceridemia, using such dsRNA compositions.
    Type: Grant
    Filed: May 14, 2019
    Date of Patent: March 2, 2021
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Brian Bettencourt, William Querbes, Kevin Fitzgerald, Maria Frank-Kamenetsky, Stuart Milstein, Svetlana Shulga Morskaya
  • Patent number: 10934162
    Abstract: There is described herein a nanomotor system and methods of use.
    Type: Grant
    Filed: November 15, 2017
    Date of Patent: March 2, 2021
    Inventors: X. Chris Le, Hongquan Zhang, Hanyong Peng, Xing-Fang Li
  • Patent number: 10916330
    Abstract: A method of designing aptamers includes building an aptamer by a seed-and-grow method optimizing screened coulomb interactions (SCI) and selecting aptamer length based on an aptamer target biological environment. Aptamers designed according to the method may comprise any DNA or RNA nucleotides. In particular, for example, aptamers may be designed according to the method to target lipids that may be found in membranes, such as liposomes or micelles. The lipids may be phosphatidylserine (PS) or phosphatidylcholine (PC).
    Type: Grant
    Filed: June 4, 2020
    Date of Patent: February 9, 2021
    Inventor: Md. Ashrafuzzaman
  • Patent number: 10907159
    Abstract: Methods of treating cancer using antisense based therapies including antisense oligonucleotides of si RNAs directed against DNA double-strand break repair proteins such as BRCA2 or RAD51 are provided. The antisense based therapies can be used alone, in tandem or in combination with other cancer therapies, in particular with therapies that lead to DNA damage, inhibition of DNA repair or inhibition of DNA synthesis, such as radiation, platinum drugs, alkylating agents, PARP inhibitors, or inhibitors of thymidylate synthase.
    Type: Grant
    Filed: December 13, 2016
    Date of Patent: February 2, 2021
    Inventors: Mark D. Vincent, Peter Ferguson, D. James Koropatnick, Mateusz Rytelewski
  • Patent number: 10907165
    Abstract: The present invention relates to methods of enhancing the translation ability and stability of an RNA molecule. The methods involve providing a cell-free composition comprising an RNA molecule to be translated, where the RNA molecule lacks an N6,2?O-dimethyladenosine (“m6Am”) residue. Also disclosed are methods of making RNA molecules and treatment methods using an RNA molecule comprising a 7-methylguanosine (“m7G”), a 5? triphosphate linker (“-ppp-”), and an N6,2?-0-dimethyladenosine (m6Am).
    Type: Grant
    Filed: October 31, 2017
    Date of Patent: February 2, 2021
    Inventors: Sarnie R. Jaffrey, Jan Mauer
  • Patent number: 10907160
    Abstract: Provided herein are methods for decreasing LRRK2 mRNA expression. Such methods are useful to ameliorate LRRK2 associated diseases. Such LRRK2 associated diseases include Parkinson's Disease, including non-LRRK2 mediated Parkinson's Disease.
    Type: Grant
    Filed: January 5, 2017
    Date of Patent: February 2, 2021
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Hien Thuy Zhao, Holly Kordasiewicz
  • Patent number: 10900041
    Abstract: The invention relates to oligonucleotides suitable for use in treating human disease. More in particular the invention—relates to antisense oligonucleotides suitable for the treatment of Alzheimer's disease.
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: January 26, 2021
    Inventors: Thomas Petrus Gerardus De Vlaam, Tsinatkeab Tadesse Hailu, Zhana Karneva
  • Patent number: 10900039
    Abstract: The present invention relates to RNAi constructs with improved tissue and cellular uptake characteristics and methods of use of these compounds in dermal applications.
    Type: Grant
    Filed: September 4, 2015
    Date of Patent: January 26, 2021
    Assignee: Phio Pharmaceuticals Corp.
    Inventor: Gerard Cauwenbergh
  • Patent number: 10876115
    Abstract: The present inventors have found microRNAs which are strongly associated with stabilization of NRF2 in tumors, and an object of the present invention is to provide means for utilizing such miRNAs for the diagnosis and treatment of cancer. The inventors conducted screening of 470 microRNAs in a microRNA library by use of HeLa cells. As a result, 8 miRNAs each exhibiting a large decrease in miRNA activity as compared with a control miRNA, and 8 miRNAs each exhibiting a large increase in miRNA activity as compared with a control miRNA, were identified. The inventors have found that the NRF2 activation in the living body, in particular tumor cells, can be detected by use of the thus-identified miRNAs, whereby malignancy of a tumor, or the like can be differentiated. The inventors have also found that a nucleic acid including a miRNA sequence associated with reduction in the aforementioned ARE activity can be used as a cancer therapeutic agent.
    Type: Grant
    Filed: January 7, 2019
    Date of Patent: December 29, 2020
    Assignee: National University Corporation Tokyo Medical and Dental University
    Inventors: Johji Inazawa, Jun Inoue, Shinsuke Yamamoto, Tatsuyuki Kawano, Ken-ichi Kozaki